N-(4-氰基-3-甲基苯基)-2-甲基-2-环氧乙烷甲酰胺 | 821765-08-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-氰基-3-甲基苯基)-2-甲基-2-环氧乙烷甲酰胺
• 英文名称: 2-methyloxirane-2-carboxylic acid (4-cyano-3-methylphenyl)amide
• 英文别名: 2-Methyl-oxirane-2-carboxylic acid (4-cyano-3-methylphenyl)amide；N-(4-cyano-3-methylphenyl)-2-methyloxirane-2-carboxamide
• CAS: 821765-08-6
• 化学式: C₁₂H₁₂N₂O₂
• 分子量: 216.239
• InChiKey: REZYIDTZSUBNHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  65.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2-fluoro-4-hydroxyphenyl)acetamide 、 N-(4-氰基-3-甲基苯基)-2-甲基-2-环氧乙烷甲酰胺 生成 3-(4-Acetylamino-3-fluorophenoxy)-N-(4-cyano-3-methylphenyl)-2-hydroxy-2-methylpropionamide
  参考文献：
  名称：

  Propionamide derivatives useful as androgen receptor modulators

  摘要：

  公式(I)的化合物公开，其中R1至R4，X和A如权利要求中所定义，并且其药学上可接受的盐和酯。公式(I)的化合物具有组织选择性雄激素受体调节剂（SARM）的作用，并且在激素疗法中非常有用，例如在男性性腺功能减退和与年龄相关的病症（如衰老期）的治疗或预防中。

  公开号：

  US20070123512A1

文献信息

• [EN] PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS<br/>[FR] DERIVES DE PROPIONAMIDE UTILISES COMME MODULATEURS DU RECEPTEUR D'ANDROGENES
  申请人：ORION CORP

  公开号：WO2005000794A1

  公开（公告）日：2005-01-06

  Compounds of formula (I) wherein R1 to R4, X and A are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g. in the treatment or prevention of male hypogonadism and age-related conditions such as andropause.

  公式（I）中的化合物，其中R1至R4、X和A的定义如权利要求所述，并且其药用盐和酯已被披露。 公式（I）的化合物具有作为组织选择性雄激素受体调节剂（SARM）的效用，并且在激素疗法中有用，例如用于治疗或预防男性性腺功能减退和与年龄相关的病症，如男性更年期。
• PROCESS FOR PREPARING BICALUTAMIDE
  申请人：Shrawat Vimal Kumar

  公开号：US20130274501A1

  公开（公告）日：2013-10-17

  The present invention provide processes for the preparation of N-[4-Cyano-3-(trifluoro methyl)phenyl]-3-[(4-fluorophenyl)sulphonyl]-2-hydroxy-2-methyl propanamide (I). The present application also provides a method of purification of N-[4-Cyano-3-(trifluoro methyl)phenyl]-3-[(4-fluorophenyl)sulphonyl]-2-hydroxy-2-methyl propanamide (I) using ethyl acetate solvent resulting in the product, substantially free from process related impurities A, B, C and D. The crystalline product of the process according to the present invention having an XRDP pattern as per FIG. 1 , is useful as an active pharmaceutical and has anti-androgenic activity.

  本发明提供了一种制备N-[4-氰基-3-(三氟甲基)苯基]-3-[(4-氟苯基)磺酰基]-2-羟基-2-甲基丙酰胺(I)的工艺。本申请还提供了一种利用乙酸乙酯溶剂纯化N-[4-氰基-3-(三氟甲基)苯基]-3-[(4-氟苯基)磺酰基]-2-羟基-2-甲基丙酰胺(I)的方法，从而得到基本上不含有工艺相关杂质A、B、C和D的产品。根据本发明的工艺得到的结晶产品具有如图1所示的X射线衍射图谱，可用作活性药物，并具有抗雄激素活性。
• PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS
  申请人：Orion Corporation

  公开号：EP1641745A1

  公开（公告）日：2006-04-05
• US8895772B2
  申请人：——

  公开号：US8895772B2

  公开（公告）日：2014-11-25
• [EN] SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF<br/>[FR] LIGANDS DE COMPOSÉS DE DÉGRADATION SÉLECTIFS DE RÉCEPTEURS DES ANDROGÈNES (SARD) ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：UNIV TENNESSEE RES FOUND

  公开号：WO2020243373A1

  公开（公告）日：2020-12-03

  This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including cyclic and heterocyclic anilide rings and their synthetic precursors, and mono-, di-, or multi-substituted N-heterocyclic rings, R-isomers, non-hydroxylated and/or non-chiral propanamides in treating androgen receptor dependent diseases and conditions such as hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.